Over Yüzey Epitelinin Seröz Tümörlerinde Fibroblast Büyüme Faktörü Reseptörü 1 (FGFR1) Amplifikasyonunun Klinik ve Histopatolojik Verilerle Değerlendirilmesi

Creative Commons License

ALAN S. (Executive) , ÖZCAN M.

Project Supported by Higher Education Institutions, 2020 - 2020

  • Project Type: Project Supported by Higher Education Institutions
  • Begin Date: February 2020
  • End Date: November 2020

Project Abstract



Aim: In this study, it is aimed to investigate the differences in expression of FGFR1 between the groups in serous cystadenomas (SC), borderline serous tumor (BST)/ atypical proliferative serous tumors (APST), low-grade serous carcinoma (LGSC) and high-grade serous carcinomas (HGSC) and its relation with prognostic factors.

Materials and methods: A total of 100 cases which diagnosed as SC (n=13), BST (n=23), LGSC (n=5) and HGSC (n=59) in Turgut Özal Medical Center between 2010 and 2020 were included in the study. Archives were used for slides, blocks and reports of the cases. BSTs and LGSKs were examined in a single group, considering their molecular characteristics and number of cases. In these cases, FGFR1 expression was investigated by RT-PCR and immunohistochemistry with sections taken from formaline fixed paraffin embedded (FFPE) tissues. Cytoplasmic and nuclear H scores were calculated for all cases in the examinations performed by immunohistochemical method.

Results: In our study, a statistically significant increase in FGFR1 gene expression in HGSC cases was found with RT-PCR compared to LGSC/BST and SK diagnosis groups (p<0,05). There was no statistically significant difference between the LGSC/BST group and the SC group fold changes (p> 0.05). The mean cytoplasmic H scores were 202.03 for the HGSC group, 134.29 for the LGSC/BST group, and 76.54 for the SK group. A weak correlation was found between fold changes obtained by RT-PCR and cytoplasmic H scores obtained by immunohistochemical staining (p <0.05).

Conclusion: It was determined that patients with FGFR1 amplification had worse prognosis. Additionally, the increased expression of FGFR1 in the malignant group was evaluated as a potential target molecule for therapies under development.


Key words: Serous ovarian tumors, FGFR1, PCR, immunohistochemistry